Nucleotide Reverse Transcriptase Inhibitors: A Thorough Review, Present Status and Future Perspective as HIV Therapeutics.

Nucleotide Reverse Transcriptase Inhibitors: A Thorough Review, Present Status and Future Perspective as HIV Therapeutics. Curr HIV Res. 2017 Nov 19;: Authors: Holec AD, Mandal S, Prathipati PK, Destache CJ Abstract Human immunodeficiency virus type-1 (HIV-1) infection leads to acquired immunodeficiency syndrome (AIDS), a severe fatal viral infection that has claimed approximately 658,507 lives in the US within the year 2010-2014. Antiretroviral (ARV) therapy has proven to inhibit HIV-1, but unlike other viral illness, not cure the infection. Among various Food and Drug Administration (FDA)-approved ARVs, nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs) are most effective in limiting HIV-1 infection. This review focuses on NRTIs mechanism of action and metabolism. We have also outlined the current classical NRTIs for HIV-1 prevention and treatment and the setbacks of NRTIs. Finally, we are also proposing various novel strategies to improve the efficacy of NRTIs, thoughtfully that will increase therapeutic efficiency of present-day HIV-1 prevention/treatment regimen. PMID: 29165087 [PubMed - as supplied by publisher]
Source: Current HIV Research - Category: Infectious Diseases Authors: Tags: Curr HIV Res Source Type: research